These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Align Technology (ALGN) has a +1.23% Earnings ESP, with its most accurate EPS estimate of $2.81 above the $2.78 consensus ahead of its October 28, 2026 report. Iovance Biotherapeutics (IOVA) has a +22.22% ESP, based on a -$0.07 estimate versus -$0.09 consensus, ahead of November 5 earnings. Both companies carry Zacks Rank #3 (Hold), and the positive ESP readings indicate potential for earnings beats, though the article provides no fundamental operating updates.

Analysis

This is weak standalone information rather than a fundamental catalyst: small estimate dispersion is easily overwhelmed by management guidance, volume/price trends, and valuation positioning. For ALGN, the relevant earnings sensitivity is clear-aligner case volumes, Invisalign mix, scanner sales, and operating leverage; a nominal EPS beat without evidence of reacceleration in adult cases or sustained margin expansion is unlikely to support a durable rerating. The 1-3 month risk is that expectations drift higher into the print while the stock remains exposed to discretionary dental demand and China execution.

IOVA's percentage estimate spread is mechanically misleading because it is calculated off a small projected loss. The tradeable issue is not whether the quarterly loss is modestly narrower, but launch trajectory for Amtagvi: treatment-center activation, patient throughput, payer approvals, manufacturing turnaround, and cash burn determine whether the company avoids future financing pressure. A revenue beat accompanied by weak treated-patient cadence or reduced cash runway would be bearish despite a headline EPS surprise.

Contrarian read: sell-side estimate signals are broadly disseminated and do not establish informational edge, particularly for two Hold-rated names. ALGN can produce a favorable one-day reaction if short positioning is elevated, but upside should fade absent forward revenue/margin guidance; IOVA has materially fatter tails, where a credible launch KPI update can move enterprise value far more than the reported EPS result. No sector-level healthcare conclusion follows from these two setup screens.

Key Decisions for Investors

• ALGN: no pre-earnings directional position solely on estimate dispersion. Build a 2-4 week post-print long only if case-volume growth, China commentary, and FY margin outlook support upward consensus revisions; invalidate if management cuts revenue or margin guidance, regardless of an EPS beat.
• ALGN relative-value watch: if ALGN rallies more than 8-10% on a low-quality EPS beat while guidance is unchanged, consider short ALGN versus long XRAY or HSIC in equal beta for 1-3 months. Thesis is multiple compression from unchanged demand rather than a call on broad dental activity; cover on a guidance raise or evidence of sustained double-digit case growth.
• IOVA: remain event-neutral into earnings unless channel work confirms accelerating treated-patient volume and treatment-center utilization. A long can be initiated only after those KPIs and cash runway improve; size as a high-volatility biotech position and exit on evidence of a financing need within the next 12 months.
• For IOVA, monitor cash burn, quarterly Amtagvi revenue, active authorized treatment centers, and management's timing to gross-margin improvement. These are the falsification variables; EPS performance is not decision-useful at the current loss level.